FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135996902> ?p ?o ?g. }

• W3135996902 endingPage "1381" @default.
• W3135996902 startingPage "1373" @default.
• W3135996902 abstract "Abstract Background This multicentre, open‐label study evaluated the efficacy and safety of antiprogrammed death ligand 1 antibody SHR‐1316 plus liposomal irinotecan and 5‐fluorouracil as the first‐line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC). Methods Eligible patients received SHR‐1316 (10 mg/kg), liposomal irinotecan (60 mg/m 2 for the first cycle, 80 mg/m 2 thereafter), and 5‐fluorouracil (2400 mg/m 2 ) every 14 days until disease progression, intolerable toxicity or withdrawal of consent. The primary endpoint was progression‐free survival (PFS). Secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. Results We enrolled 23 patients between 11 March 2019 and 31 May 2019. The median follow‐up duration was 15.2 months (95% CI 14.2–16.2). The median PFS was 8.5 months (95% CI 1.2–15.8), and ORR and DCR were 52.2% (95% CI 30.1–74.3) and 73.9% (95% CI 54.5–93.3), respectively. The median OS was 11.6 months (95% CI 6.7–16.6). The most common treatment‐related grade 3–4 adverse events (AEs) were neutropenia (17.4%), nausea (13.0%), and anorexia (13.0%). Treatment‐related serious AEs occurred in two patients. No treatment‐related deaths occurred. Conclusions SHR‐1316 plus liposomal irinotecan and 5‐fluorouracil has a promising efficacy and manageable safety profile, and could be a new first‐line treatment approach for patients with unresectable locally advanced or distant metastatic ESCC." @default.
• W3135996902 created "2021-03-29" @default.
• W3135996902 creator A5022938518 @default.
• W3135996902 creator A5029848730 @default.
• W3135996902 creator A5037870558 @default.
• W3135996902 creator A5060002817 @default.
• W3135996902 creator A5063952694 @default.
• W3135996902 creator A5065195779 @default.
• W3135996902 creator A5066887020 @default.
• W3135996902 creator A5071719170 @default.
• W3135996902 creator A5077068949 @default.
• W3135996902 date "2021-03-24" @default.
• W3135996902 modified "2023-09-27" @default.
• W3135996902 title "<scp>SHR‐1316</scp> , an <scp>anti‐PD‐L1</scp> antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase <scp>2</scp> study" @default.
• W3135996902 cites W1978674311 @default.
• W3135996902 cites W2015355568 @default.
• W3135996902 cites W2024114545 @default.
• W3135996902 cites W2027298808 @default.
• W3135996902 cites W2042844347 @default.
• W3135996902 cites W2116435502 @default.
• W3135996902 cites W2128035403 @default.
• W3135996902 cites W2129322568 @default.
• W3135996902 cites W2144020449 @default.
• W3135996902 cites W2160834915 @default.
• W3135996902 cites W2187917981 @default.
• W3135996902 cites W2490916482 @default.
• W3135996902 cites W2596604644 @default.
• W3135996902 cites W2603997054 @default.
• W3135996902 cites W2745624257 @default.
• W3135996902 cites W2749884966 @default.
• W3135996902 cites W2766673799 @default.
• W3135996902 cites W2767857925 @default.
• W3135996902 cites W2789258259 @default.
• W3135996902 cites W2793364080 @default.
• W3135996902 cites W2794788563 @default.
• W3135996902 cites W2889646458 @default.
• W3135996902 cites W2897422388 @default.
• W3135996902 cites W2906166963 @default.
• W3135996902 cites W2946386783 @default.
• W3135996902 cites W2972212968 @default.
• W3135996902 cites W2976652879 @default.
• W3135996902 cites W2997633146 @default.
• W3135996902 cites W3025003676 @default.
• W3135996902 cites W3081696843 @default.
• W3135996902 cites W3087784988 @default.
• W3135996902 doi "https://doi.org/10.1111/1759-7714.13913" @default.
• W3135996902 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8088918" @default.
• W3135996902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33760397" @default.
• W3135996902 hasPublicationYear "2021" @default.
• W3135996902 type Work @default.
• W3135996902 sameAs 3135996902 @default.
• W3135996902 citedByCount "13" @default.
• W3135996902 countsByYear W31359969022022 @default.
• W3135996902 countsByYear W31359969022023 @default.
• W3135996902 crossrefType "journal-article" @default.
• W3135996902 hasAuthorship W3135996902A5022938518 @default.
• W3135996902 hasAuthorship W3135996902A5029848730 @default.
• W3135996902 hasAuthorship W3135996902A5037870558 @default.
• W3135996902 hasAuthorship W3135996902A5060002817 @default.
• W3135996902 hasAuthorship W3135996902A5063952694 @default.
• W3135996902 hasAuthorship W3135996902A5065195779 @default.
• W3135996902 hasAuthorship W3135996902A5066887020 @default.
• W3135996902 hasAuthorship W3135996902A5071719170 @default.
• W3135996902 hasAuthorship W3135996902A5077068949 @default.
• W3135996902 hasBestOaLocation W31359969023 @default.
• W3135996902 hasConcept C121608353 @default.
• W3135996902 hasConcept C126322002 @default.
• W3135996902 hasConcept C141071460 @default.
• W3135996902 hasConcept C143998085 @default.
• W3135996902 hasConcept C168563851 @default.
• W3135996902 hasConcept C197934379 @default.
• W3135996902 hasConcept C203092338 @default.
• W3135996902 hasConcept C2776694085 @default.
• W3135996902 hasConcept C2777063308 @default.
• W3135996902 hasConcept C2778850193 @default.
• W3135996902 hasConcept C2780259306 @default.
• W3135996902 hasConcept C2780456651 @default.
• W3135996902 hasConcept C2780580376 @default.
• W3135996902 hasConcept C31760486 @default.
• W3135996902 hasConcept C526805850 @default.
• W3135996902 hasConcept C71924100 @default.
• W3135996902 hasConcept C90924648 @default.
• W3135996902 hasConceptScore W3135996902C121608353 @default.
• W3135996902 hasConceptScore W3135996902C126322002 @default.
• W3135996902 hasConceptScore W3135996902C141071460 @default.
• W3135996902 hasConceptScore W3135996902C143998085 @default.
• W3135996902 hasConceptScore W3135996902C168563851 @default.
• W3135996902 hasConceptScore W3135996902C197934379 @default.
• W3135996902 hasConceptScore W3135996902C203092338 @default.
• W3135996902 hasConceptScore W3135996902C2776694085 @default.
• W3135996902 hasConceptScore W3135996902C2777063308 @default.
• W3135996902 hasConceptScore W3135996902C2778850193 @default.
• W3135996902 hasConceptScore W3135996902C2780259306 @default.
• W3135996902 hasConceptScore W3135996902C2780456651 @default.
• W3135996902 hasConceptScore W3135996902C2780580376 @default.
• W3135996902 hasConceptScore W3135996902C31760486 @default.
• W3135996902 hasConceptScore W3135996902C526805850 @default.
• W3135996902 hasConceptScore W3135996902C71924100 @default.

• next